Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Epidemiological Patterns and Disease Burden of MASLD, MetALD, and ALD.

Clinical and molecular hepatology·2026
Same author

Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction-Associated Steatotic Liver Disease.

The Kaohsiung journal of medical sciences·2026
Same author

Dietary Guidelines 2025-2030 For Americans Are Concerning For Liver Health.

The American journal of gastroenterology·2026
Same author

Development and Validation of the Steatotic Liver Disease Lab Data Index: A Refined Diagnostic Tool.

Canadian journal of gastroenterology & hepatology·2026
Same author

Burden and Regional Disparities of MASH-Related Liver Cancer in the Asia-Pacific Region From 1990 to 2023.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis.

The American journal of gastroenterology·2026

Related Experiment Videos

Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.

George Papatheodoridis1,2, Maria Buti1,3, Yusuf Yilmaz1,4

  • 1The Global NASH/MASH and Global Liver Councils, Washington, DC, USA.

Journal of Gastroenterology and Hepatology
|July 8, 2026
PubMed
Summary

Approximately half of patients with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) also have metabolic dysfunction-associated steatotic liver disease (MASLD). This co-occurrence significantly worsens patient-reported outcomes, emphasizing the need for integrated care.

Keywords:
CLDQHRQLfatiguesystemic symptomswork productivityworry

Related Experiment Videos

Area of Science:

  • Hepatology
  • Internal Medicine
  • Clinical Research

Background:

  • Hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic dysfunction-associated steatotic liver disease (MASLD) are prevalent liver conditions.
  • Understanding the impact of superimposed MASLD on patients with chronic viral hepatitis is crucial for comprehensive care.

Purpose of the Study:

  • To evaluate the clinical characteristics and patient-reported outcomes (PROs) of HBV and HCV patients with and without MASLD.
  • To identify the association between MASLD and PROs in chronic viral hepatitis cohorts.

Main Methods:

  • A cross-sectional study analyzed data from the Global Liver Registry, including clinical information and PRO questionnaires (FACIT-F, CLDQ, WPAI).
  • MASLD was defined using the Hepatic Steatosis Index (HSI) ≥ 36 and at least one cardiometabolic risk factor.
  • Included patients with HBV (n=2063) and HCV (n=2586).

Main Results:

  • Nearly half of HBV (49%) and HCV (47%) patients had MASLD.
  • HBV patients with MASLD showed more advanced fibrosis and significantly lower PRO scores, particularly in fatigue domains.
  • HCV patients with MASLD reported worse physical well-being and quality of life, with notable impairments in systemic symptoms and worry domains.

Conclusions:

  • MASLD is common in patients with chronic viral hepatitis (HBV/HCV) and is independently associated with worse patient-reported outcomes.
  • Proactive metabolic assessment and management are essential for improving the well-being of patients with chronic viral hepatitis and MASLD.